ERS Genomics licenses gene editing tech to G+FLAS

By The Science Advisory Board staff writers

ERS Genomics has signed a nonexclusive licensing deal granting G+FLAS Life Sciences access to its CRISPR/Cas9 patent portfolio.

G+FLAS is applying CRISPR technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way. These products include plant-based trastuzumab, a biosimilar antibody, and a cas9 monoclonal antibody to be used to test the development of Cas9-based gene therapy products.

ERS Genomics holds the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?